Barry Paul

Aug 23, 2024 | mdpi.com | Barry Paul |Faiz Anwer |Shahzad Raza |Aytaj Mammadzadeh

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Feb 13, 2023 | futuremedicine.com | Barry Paul |Michaela Liedtke |Jack Khouri |Robert Rifkin

Future OncologyAhead of PrintClinical Trial ProtocolOpen Access, , , , , , , , , , , , , , , & AbstractMagrolimab is a monoclonal antibody that blocks CD47, a ‘do not eat me’ signal overexpressed on tumor cells. CD47 is overexpressed in multiple myeloma (MM), which contributes to its pathogenesis. Preclinical studies have shown that CD47 blockade induces macrophage activation, resulting in elimination of myeloma cells, and that there is synergy between magrolimab and certain anticancer therapies.